Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) registered a 3.33% increase, still its new closing price is 10.71% up from the company’s 1 year high of 1.12.It posted 3.33% gains in previous 5 sessions and is now the subject of 0 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 2 stock analysts following this company have an average price target at $1.25, with individual PT in the $1.00-$1.50 range. The shares moved at $0.31, implying that brokerage firms see shares losing about -66.30% in twelve months time.
Peregrine Pharmaceuticals, Inc. (PPHM) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a 0.00% rise year to date. A Director at Peregrine Pharmaceuticals, Inc. (PPHM) acquired shares in a transaction closed on Wednesday March 14, 2012. SWARTZ ERIC S bought 16,000 shares in the company at $0.62 each and collected $9,001 in proceeds. SWARTZ ERIC S now owns 672,118 shares in the company after this transaction. A Director in the company, SWARTZ ERIC S, disclosed a transaction on Monday November 08, 2010 that ended up paying $16,000 from the purchase of 10,000 shares at $1.6 per share.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) Upcoming Results on Tap
Peregrine Pharmaceuticals, Inc. will next provide financial results for the January 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.03 in that period. Sales during the quarter are predicted to arrive at $14 million.
Peregrine Pharmaceuticals, Inc. (PPHM) Brokerage Update
Over the last six months and over the last three months, the shares of Peregrine Pharmaceuticals, Inc. (PPHM), have changed -13.89% and -8.82%, respectively.